Aurora Cannabis Secures EU Rights for Innovative Cannabis Varieties Farm Gas™ and Sourdough™
- Aurora Cannabis secured community plant variety rights for two proprietary cannabis varieties, enhancing its genetic portfolio.
- The awarded cultivars, Farm Gas™ and Sourdough™, boast high potency and appealing aromas for medical patients.
- This recognition positions Aurora for growth in Europe and reinforces its leadership in the medical cannabis sector.
Aurora Cannabis Secures Community Plant Variety Rights for Innovative Cannabis Varieties
Aurora Cannabis Inc., a prominent player in the global medical cannabis sector, recently achieves a significant milestone by securing community plant variety rights from the EU's Community Plant Variety Office for two of its proprietary cannabis varieties. The awarded cultivars, named SOT20R07-007 (Farm Gas™) and ACB21T044 (Sourdough™), represent Aurora's commitment to advancing cannabis genetics through rigorous breeding and phenotyping programs. This recognition not only highlights the scientific excellence at Aurora's Aurora Coast R&D facility but also fortifies its position as a leader in the cannabis industry.
Both Farm Gas™ and Sourdough™ exhibit desirable traits such as high potency, appealing aromas, and robust bud structures, making them well-suited for medical patients across various European markets, including Germany, Poland, the UK, Canada, and Australia. Lana Culley, Aurora's VP of Innovation and International Operations, emphasizes that this award underscores the superior genetic work being done at Aurora and enhances the company's global genetics portfolio. By gaining exclusive control over the commercial production and sale of these varieties across the EU’s 27 member states, Aurora is well-positioned to leverage its extensive investments in scientific research and innovation.
The implications of this recognition extend beyond mere accolades; it strategically positions Aurora for growth in Europe, a dynamic and expanding market for medical cannabis. With existing rights in Canada and other territories, the company’s robust genetics platform is pivotal to its leadership in the medical cannabis space. By consistently delivering high-quality products, Aurora enhances patient access to premium cannabis, reinforcing its status as a pioneer in the industry. This advancement not only marks a step forward for Aurora but also contributes to the broader evolution of cannabis genetics on a global scale.
In addition to the recognition from the EU, Aurora's innovative approach to cannabis breeding is indicative of the growing emphasis on quality and consistency in the medical cannabis sector. The company's ability to commercialize its cultivars globally showcases a strategic foresight that could shape future developments in cannabis research and market expansion.
Overall, Aurora Cannabis’s recent achievement underscores its commitment to innovation, quality, and patient care, solidifying its reputation as a leader in cannabis genetics and paving the way for future advancements in the industry.
